Fundraising FoxHilleVax
Acquired6 known investors
Find your way into HilleVax
Sign up to see every warm intro you have to HilleVax
- Paths you didn't know you had: your email and LinkedIn already hold routes to the HilleVax team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding. It holds a portfolio of 120+ assets and serves biotech companies developing drug candidates.
Investors · 6
How we know: Catalys Pacific's portfolio page · Not right? Tell us
How we know: Frazier Life Sciences's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Lightspeed Venture Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · renaissancecapital.com · Not right? Tell us
Frequently asked questions
- What does HilleVax do?
- XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding. It holds a portfolio of 120+ assets and serves biotech companies developing drug candidates.
- Who are HilleVax's investors?
- HilleVax's investors include Catalys Pacific, Frazier Life Sciences, Lightspeed Venture Partners, RA Capital, Samsara BioCapital, Frazier Healthcare Partners.